

Lab Normal Ranges

CMP			Chemistry			CBC w/Differential/Platelets		
AST - Males	12-47	IU/L	ANA Screen	Negative		WBC	4.0-11.0	k/mm ³
AST - Females	11-40	IU/L	C-Reactive Protein (CRP)	<4.9	mg/L	RBC - Males	4.3-6.0	m/mm ³
ALT - Males	5-60	IU/L	Erythropoietin	2.6-18.5	mU/mL	RBC - Females	3.7-5.4	m/mm ³
ALT - Females	5-46	IU/L	Potassium	3.6-5.3	mmol/L	Hemoglobin - Males	13.0-18.0	g/dL
Calcium	8.7-10.4	mg/dL	Lactic Dehydrogenase (LDH)	112-245	IU/L	Hemoglobin - Females	11.5-16.0	g/dL
GGT - Males	5-80	IU/L	Magnesium	1.5-2.5	mg/dL	Hematocrit - Males	40.0-53.0	%
GGT - Females	5-60	IU/L	Phosphorus (>17 y)	2.4-4.8	mg/dL	Hematocrit - Females	35.0-48.0	%
Total Bilirubin	≤1.3	mg/dL	Glucose	70-99	mg/dL	MCV	78-100	fL
Total Protein (4-49 y)	6.3-8.0	g/dL	Carbon Dioxide (CO ₂)	20-31	mmol/L			
Total Protein (≥50 y)	6.0-7.7	g/dL	Chloride (1-59 y)	98-108	mmol/L	MCH	27.0-34.0	Pg
Albumin	3.8-5.1	g/dL	Chloride (≥60)	95-109	mmol/L	MCHC	31.0-37.0	g/dL
BUN - Male (1-49 y)	7-21	mg/dL	Uric Acid - Males	3.7-7.7	mg/dL	RDW (cv)	11.0-15.0	%
BUN - Female (1-49 y)	6-19	mg/dL	Uric Acid - Females	2.5-6.2	mg/dL	RDW (sd)	38.0-49.0	fL
BUN (50-69 y)	7-28	mg/dL	Hepatitis Panel, Acute			Platelet Count	130-450	thous/mm ³
BUN (≥70 y)	8-36	mg/dL	Hepatitis A Ab, IgM	Non-Reactive		MPV	7.5-14.0	fL
Sodium	135-145	mmol/L	Hepatitis B Core Ab, IgM	Non-Reactive		Reticulocyte	0.7-2.8	%
Alk. Phos - Males	40-140	IU/L	Hepatitis B Surface Antigen	Non-Reactive		Neutrophils	40-85	%
Alk. Phos. - Females (18-49 y)	37-127	IU/L	Hepatitis C Ab	≤0.80 - Nonreactive		Neutrophils Absolute	1.60-9.30	k/uL
Alk. Phos. - Females (>50 y)	42-146	IU/L	Coagulation			Lymphocytes	10-45	%
Creatinine, Timed Urine (13-17 y)	0.3-1.9	g/day	Prothrombin Time	9.4-12.5	Seconds	Lymphocytes Absolute	0.60-5.50	k/uL
Creatinine, Timed Urine- Male (>18 y)	0.8-2.0	g/day	INR	0.9-1.1		Monocytes	3-15	%
Creatinine, Timed Urine- Female (>18 y)	0.6-1.8	g/day	APTT	24.0-36.5	Seconds	Monocytes Absolute	0.10-1.60	k/uL
Hepatitis B Surface AB, Quant	CDC guidelines indicate values equal to or greater than 10 mIU/mL indicate immunity.					Eosinophils	0-7	%
BUN/Creat. Ratio	10-28	mg/dL	Sedimentation Rate			Eosinophils Absolute	0.0-0.7	k/uL
A/G Ratio	1.0-2.4	g/dL	*Males			Basophils	0-2	%
Anion Gap	4-18		11-50 yrs	0-15	mm/Hr	Basophils Absolute	0.0-0.2	k/uL
Globulin	2.0-3.7	g/dL	51 yrs & above	0-20	mm/Hr	Immature Granulocytes	0-1	%
GFR Estimated (Non-African American)	≥60	mL/min/1.73m ²				Immature Granulocytes Absolute	0.00-0.10	k/uL
GRF Estimated (African American)	>60	mL/min/1.73m ² L	*Females			NRBC RE	0-1	%
Creatinine - Males	0.6-1.5	mg/dL	11-50 yrs	0-20	mm/Hr			
Creatinine - Females	0.6-1.4	mg/dL	51 yrs & above	0-30	mm/Hr			

Lab Normal Ranges

			Immunochemistry/Chemistry			Miscellaneous		
Bilirubin, Direct	≤ 0.3	mg/dL	T3, Free, Non-Dialysis	2.0-4.8	pg/mL	Amylase, Serum	31-107	IU/L
Cytomegalovirus Antibodies, IgG and IgM CMV IgG: Negative: ≤0.8 Equivocal: 0.9-1.0 Positive: ≥1.1 CMV IgM: Negative: ≤0.8 Equivocal: 0.9-1.0 Positive: ≥1.1			T4, Free, Non-Dialysis	0.8-1.7	ng/dL	Lipase	13-60	IU/L
			T3 Total (>19 y)	80-200	ng/dL	CEA	<3.5	ng/mL
			Estradiol			Thyroxine (T4)	4.9-11.1	ug/dL
Female (18 years & Above) Follicular 12-233 pg/mL Ovulation 41-398 pg/mL Luteal 22-341 pg/mL Postmenopausal <139 pg/mL Pregnancy (1st Trimester) 154-3243 pg/mL Pregnancy (2nd Trimester) 1561-21,280 pg/mL Pregnancy (3rd Trimester) >8525 pg/mL Male (18 Years & Above) <45 pg/mL								
Ferritin Male	25-506	ng/mL	TSH	0.45-4.50	mU/L	CA 19-9	<36	U/mL
Ferritin Female (Up to 49 years)	11-230	ng/mL	B12	232-1245	pg/mL	CA 27.29	<38	U/mL
Ferritin Female (50 years & above)	14-313	ng/mL	Creatine Kinase Male (10-17 y)	≤250	IU/L	Total Cholesterol	<200	mg/dL
FSH Male 18 Years & Above 1.5-12.4 mIU/mL Female 18 Years & Above Follicular: 3.5-12.5 mIU/mL Midcycle: 4.7-21.5 mIU/mL Luteal: 1.7-7.7 mIU/mL			Creatine Kinase Female (10-17 y)	≤144	IU/L	HDL Cholesterol - Males	≥40	mg/dL

Lab Normal Ranges

Postmenopausal: 25.8-134.8 mIU/mL							
HIV 1/2 Ag and Abs, Fourth Generation, w/Reflexes	Non-reactive		Creatine Kinase Male (≥18 y)	≤308	IU/L	HDL Cholesterol - Females	≥50 mg/dL
Lipoprotein (a)	<75	nmol/L	Creatine Kinase Female (≥18 y)	≤192	IU/L	LDL Cholesterol (0-19 y)	≤109 mg/dL
hCG Quantitative Non-pregnant ovulating female: =4 mIU/mL Non-pregnant postmenopausal female: =10 mIU/mL Male: =2 mIU/mL			Glycohemoglobin A1c	<5.7	%	LDL Cholesterol (20-150 y)	≤99 mg/dL
Pregnancy, Qualitative, Urine	Negative		ADA's Goal for Therapy	<7.0	%	Triglycerides	<150 mg/dL
Iron and Transferrin w/%Saturation Male >20 Years & above	40-190	ug/dL	Exceeds ADA's Goal for Therapy	7.0-8.0	%	Retic Count w/RET-HE	RET-He: 4-150 years: 30.5-41.0 pg IRF: 0-150 years: 2.5-16.0 %
Iron and Transferrin w/%Saturation Female >20 Years & above	35-175	ug/dL	ADA recommends re-evaluation of therapy	>8.0	%	Direct Coombs, Polyspecific	Negative
Transferrin (>16 years & above)	200-390	mg/dL	Phosphorus Urine, Random - Male	60-800	mg/g Creat	Direct Coombs, Reflexive	Negative
% Saturation	15-45%		Phosphorus Urine, Random - Female	120-1020	mg/g Creat		
			Phosphorus Urine, Timed	0.4-1.3	g/day		